4.7 Review

Increased CNV-Region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample

Journal

GENOMICS
Volume 102, Issue 2, Pages 112-122

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygeno.2013.04.004

Keywords

Alzheimer's disease; Copy Number Variable Regions (CNV-Regions); Copy Number Variations (CNVs); Genome-wide scan; Next Generation Sequencing (NGS)

Funding

  1. Pfizer Inc.
  2. Wyeth Research
  3. Bristol-Myers Squibb
  4. Eli Lilly and Company
  5. GlaxoSmithKline
  6. Merck Co. Inc.
  7. AstraZeneca AB
  8. Novartis Pharmaceuticals Corporation
  9. Alzheimer's Association
  10. Eisai Global Clinical Development
  11. Elan Corporation plc
  12. Forest Laboratories
  13. Institute for the Study of Aging
  14. U.S. Food and Drug Administration
  15. Foundation for the National Institutes of Health
  16. Transdisciplinary Imaging Genetics Center [TIGC-P20 RR020837-01]
  17. Alzheimer's Disease Neuroimaging Initiative [ADNI U01 AG024904-01, 3U01AG024904-0355]
  18. National Institute of Aging
  19. National Institute of Biomedical Imaging and Bioengineering (NIH)
  20. Function Imaging Biomedical Informatics Research Network (National Center for Research Resources) [FBIRN U24-RR021992]
  21. Vanda Pharmaceuticals
  22. Alzheimer's Disease Neuroimaging Initiative (ADNI)
  23. National Institute on Aging
  24. National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Ask authors/readers for more resources

We investigated the genome-wide distribution of CNVs in the Alzheimer's disease (AD) Neuroimaging Initiative (ADNI) sample (146 with AD, 313 with Mild Cognitive Impairment (MCI), and 181 controls). Comparison of single CNVs between cases (MCI and AD) and controls shows overrepresentation of large heterozygous deletions in cases (p-value < 0.0001). The analysis of CNV-Regions identifies 44 copy number variable loci of heterozygous deletions, with more CNV-Regions among affected than controls (p = 0.005). Seven of the 44 CNV-Regions are nominally significant for association with cognitive impairment. We validated and confirmed our main findings with genome re-sequencing of selected patients and controls. The functional pathway analysis of the genes putatively affected by deletions of CNV-Regions reveals enrichment of genes implicated in axonal guidance, cell-cell adhesion, neuronal morphogenesis and differentiation. Our findings support the role of CNVs in AD, and suggest an association between large deletions and the development of cognitive impairment (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available